S. Kroll

发表

p53 gene and cell cycling in uveal melanoma.

K. Kishore, S. Ghazvini, D. Char, 1996, American journal of ophthalmology.

Doxorubicin plus evofosfamide versus doxorubicin alone in locally advanced, unresectable or metastatic soft-tissue sarcoma (TH CR-406/SARC021): an international, multicentre, open-label, randomised phase 3 trial.

Robin L. Jones, W. Read, H. Tawbi, 2017, The Lancet. Oncology.

Abstract LB-121: Randomized phase II study of the efficacy and safety of gemcitabine + TH-302 (G+T) vs gemcitabine (G) alone in previously untreated patients with advanced pancreatic cancer

M. Borad, D. Ryan, S. Kroll, 2012 .

A Phase I Study of the Safety and Pharmacokinetics of the Hypoxia-Activated Prodrug TH-302 in Combination with Doxorubicin in Patients with Advanced Soft Tissue Sarcoma

K. Ganjoo, S. Kroll, S. Okuno, 2011, Oncology.

A Phase 1 dose-escalation trial of glufosfamide in combination with gemcitabine in solid tumors including pancreatic adenocarcinoma

J. Hamm, S. Kroll, E. Chiorean, 2008, Cancer Chemotherapy and Pharmacology.

Prognostic factors in adult soft-tissue sarcomas of the head and neck.

M. Kaplan, K. Fu, T. Phillips, 1997, International journal of radiation oncology, biology, physics.

Radiotherapy for high grade clinically localized adenocarcinoma of the prostate.

M. Roach, E. Small, S. Kroll, 1996, The Journal of urology.

Resolution of Cullen's sign in patient with metastatic melanoma responding to hypoxia-activated prodrug TH-302

G. Weiss, S. Kroll, K. Lewandowski, 2011, Dermatology reports.

Phase I study of evofosfamide, an investigational hypoxia‐activated prodrug, in patients with advanced leukemia

M. Konopleva, M. Andreeff, H. Kantarjian, 2016, American journal of hematology.

Cytomorphometry of uveal melanomas: fine needle aspiration biopsy versus standard histology.

D. Char, S. Kroll, J. B. Crawford, 1989, Transactions of the American Ophthalmological Society.

Ki-67 and bromodeoxyuridine labeling of human choroidal melanoma cells.

D. Char, S. Kroll, D. Bardenstein, 1991, Current eye research.

Five-year follow-up of helium ion therapy for uveal melanoma.

J. Quivey, D. Char, S. Kroll, 1990, Archives of ophthalmology.

Iodine-131 Tositumomab For Patients With Small Lymphocytic Lymphoma (SLL): Overall Clinical Trial Experience

M. Kaminski, T. Lister, S. Kroll, 2000 .

John M Bennett, J. Armitage, J. Connors, 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Orbital metastases: diagnosis and course

D. Char, S. Kroll, T. Miller, 1997, The British journal of ophthalmology.

A Phase I/II Study of Evofosfamide, A Hypoxia-activated Prodrug with or without Bortezomib in Subjects with Relapsed/Refractory Multiple Myeloma

J. Laubach, P. Richardson, S. Kroll, 2018, Clinical Cancer Research.

Long-term follow-up after uveal melanoma charged particle therapy.

D. Char, S. Kroll, J. Castro, 1997, Transactions of the American Ophthalmological Society.

Effect of various doses of radiation for uveal melanoma on regression, visual acuity, complications, and survival.

J. Quivey, T. Phillips, D. Char, 1989, American journal of ophthalmology.

Pivotal study of iodine I 131 tositumomab for chemotherapy-refractory low-grade or transformed low-grade B-cell non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparative analysis of proliferating cell nuclear antigen, bromodeoxyuridine, and mitotic index in uveal melanoma.

S. Ghazvini, D. Char, S. Kroll, 1995, Investigative ophthalmology & visual science.

Late radiation failures after iodine 125 brachytherapy for uveal melanoma compared with charged-particle (proton or helium ion) therapy.

J. Quivey, T. Phillips, D. Char, 2002, Ophthalmology.

Iris melanomas. Diagnostic problems.

D. Char, S. Kroll, J. B. Crawford, 1996, Ophthalmology.

Anterior segment complications after helium ion radiation therapy for uveal melanoma. Radiation cataract.

E. Blakely, D. Char, S. Kroll, 1994, Archives of ophthalmology.

[The German keratomycosis registry : Initial results of a multicenter survey].

B. Seitz, A. Viestenz, S. Kroll, 2019, Der Ophthalmologe : Zeitschrift der Deutschen Ophthalmologischen Gesellschaft.

Das Deutsche Pilz-Keratitis-Register

B. Seitz, A. Viestenz, S. Kroll, 2019, Der Ophthalmologe.

Penetrating keratoplasty for keratoconus

D. Char, S. Kroll, J. Castro, 2007 .

Long-term effects of radiotherapy in childhood and adolescence.

N. Jaffe, S. Kroll, D. Larson, 1990, American journal of surgery.

The effect of silicone nasolacrimal intubation on epiphora after helium ion irradiation of uveal melanomas.

D. Char, S. Kroll, J. Castro, 1989, American journal of ophthalmology.

Influence of fraction size, total dose, and overall time on local control of T1-T2 glottic carcinoma.

J. Quivey, K. Fu, T. Phillips, 1997, International journal of radiation oncology, biology, physics.

A phase I dose-escalation trial of 2-deoxy-d-glucose alone or combined with docetaxel in patients with advanced solid tumors

J. Schlesselman, R. DiPaola, K. Papadopoulos, 2013, Cancer Chemotherapy and Pharmacology.

Cell cycling and prognosis in uveal melanoma.

J. O'Brien, S. Ghazvini, D. Char, 1995, Clinical cancer research : an official journal of the American Association for Cancer Research.

Hypoxia-activated evofosfamide for treatment of recurrent bevacizumab-refractory glioblastoma: a phase I surgical study

Shiliang Huang, A. Brenner, S. Kroll, 2018, Neuro-oncology.

Comparative genomic hybridization in the detection of DNA copy number abnormalities in uveal melanoma.

J. Gray, J. O'Brien, J. Gray, 1994, Cancer research.

Comparative genomic hybridization analysis of archival formalin-fixed paraffin-embedded uveal melanomas.

D. Pinkel, F. Waldman, F. Waldman, 1996, Cancer genetics and cytogenetics.

Anterior segment sparing to reduce charged particle radiotherapy complications in uveal melanoma.

L. Verhey, P. Petti, E. Blakely, 1997, International journal of radiation oncology, biology, physics.

Uveal melanoma radiation. 125I brachytherapy versus helium ion irradiation.

J. Quivey, T. Phillips, D. Char, 1989, Ophthalmology.

Ten-year follow-up of helium ion therapy for uveal melanoma.

D. Char, S. Kroll, J. Castro, 1998, American journal of ophthalmology.

Retinoblastoma cell cycling.

F. Waldman, D. Char, S. Kroll, 1991, Cytometry.

Abbreviated chemotherapy with fludarabine followed by tositumomab and iodine I 131 tositumomab for untreated follicular lymphoma.

J. Leonard, E. Cesarman, S. Vallabhajosula, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

131I-tositumomab therapy as initial treatment for follicular lymphoma.

Richard L Wahl, M. Kaminski, R. Wahl, 2005, The New England journal of medicine.

Tositumomab and iodine I 131 tositumomab for recurrent indolent and transformed B-cell non-Hodgkin's lymphoma.

T. Lister, J. Radford, A. Rohatiner, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Assessment of treatment-related myelodysplastic syndromes and acute myeloid leukemia in patients with non-Hodgkin lymphoma treated with tositumomab and iodine I131 tositumomab.

J. Vose, A. Zelenetz, M. Kaminski, 2005, Blood.

Pivotal S tudy o f I odine I 1 31 T ositumomab f or Chemotherapy-Ref ractory L ow-Grade o r T ransformed Low-Grade B -Cell N on-Hodgkin's L ymphomas

J. Vose, A. Zelenetz, M. Kaminski, 2001 .

Radioimmunotherapy with iodine (131)I tositumomab for relapsed or refractory B-cell non-Hodgkin lymphoma: updated results and long-term follow-up of the University of Michigan experience.

M. Kaminski, R. Wahl, I. Francis, 2000, Blood.

Radiation pneumonitis following combined modality therapy for lung cancer: analysis of prognostic factors.

D. Gandara, T. Phillips, M. Roach, 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Helium ions versus iodine 125 brachytherapy in the management of uveal melanoma. A prospective, randomized, dynamically balanced trial.

J. Quivey, T. Phillips, D. Char, 1993, Ophthalmology.

Randomized phase 3, multicenter, open-label study comparing evofosfamide (Evo) in combination with doxorubicin (D) vs. D alone in patients (pts) with advanced soft tissue sarcoma (STS): Study TH-CR-406/SARC021

Robin L. Jones, A. Italiano, R. Riedel, 2016 .

Tositumomab and iodine-131 tositumomab produces durable complete remissions in a subset of heavily pretreated patients with low-grade and transformed non-Hodgkin's lymphomas.

J. Vose, A. Zelenetz, M. Kaminski, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The Radioisotope Contributes Significantly to the Activity of Radioimmunotherapy

A. Zelenetz, M. Kaminski, J. Leonard, 2004, Clinical Cancer Research.

Treatment-Relate d M yelodysplasia a nd A cute L eukemia i n Non-Hodgkin's L ymphoma P atients

J. Armitage, J. Connors, J. Bennett, 2003 .

Failure of preenucleation radiation to decrease uveal melanoma mortality.

T. Phillips, D. Char, S. Kroll, 1988, American journal of ophthalmology.

Efficacy and safety of tositumomab and iodine-131 tositumomab (Bexxar) in B-cell lymphoma, progressive after rituximab.

S. Horning, M. Goris, D. Podoloff, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A Phase 2 Trial of Glufosfamide in Combination With Gemcitabine in Chemotherapy-Naive Pancreatic Adenocarcinoma

J. Hamm, C. Barrios, S. Kroll, 2009, American journal of clinical oncology.

Abstract GS4-01: Results from CONTESSA: A phase 3 study of tesetaxel plus a reduced dose of capecitabine versus capecitabine alone in patients with HER2-, hormone receptor + (HR+) metastatic breast cancer (MBC) who have previously received a taxane

P. Fasching, Sung-Bae Kim, M. Piccart, 2021 .

Preliminary safety and efficacy of TH-302, an investigational hypoxia-targeted drug, and dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RR MM).

J. Laubach, P. Richardson, P. Armand, 2014 .

Metastatic risk for distinct patterns of postirradiation local recurrence of posterior uveal melanoma.

J. Quivey, J. Harbour, D. Char, 1997, Ophthalmology.

Uveal Melanoma: Growth Rate and Prognosis

T. Phillips, D. Char, S. Kroll, 1997 .

Re-treatment with I-131 tositumomab in patients with non-Hodgkin's lymphoma who had previously responded to I-131 tositumomab.

M. Kaminski, J. Leonard, R. Wahl, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Dose-attenuated radioimmunotherapy with tositumomab and iodine 131 tositumomab in patients with recurrent non-Hodgkin's lymphoma (NHL) and extensive bone marrow involvement

J. Leonard, S. Vallabhajosula, S. Kroll, 2007, Leukemia & lymphoma.

Ultrasonographic measurement of uveal melanoma thickness: interobserver variability.

D. Char, S. Kroll, D H Char, 1990, The British journal of ophthalmology.

Randomized trial of radiation for age-related macular degeneration.

J. Quivey, T. Phillips, D. Char, 1999, American journal of ophthalmology.

Natural history of indeterminate pigmented choroidal tumors.

D. Char, S. Kroll, M. Zarbin, 1994, Ophthalmology.

Irradiated uveal melanomas: cytopathologic correlation with prognosis.

J. Quivey, D. Char, S. Kroll, 1996, American journal of ophthalmology.

Diabetic radiation morbidity.

D. Char, S. Kroll, J. Castro, 1992, The British journal of ophthalmology.

Responses to the combination of the glycolytic inhibitor 2-deoxy-glucose (2DG) and docetaxel (DC) in patients with lung and head and neck (H/N) carcinomas

K. Papadopoulos, S. Kroll, T. Lampidis, 2007 .

Randomized Phase II Trial of Gemcitabine Plus TH-302 Versus Gemcitabine in Patients With Advanced Pancreatic Cancer.

M. Borad, D. Ryan, S. Kroll, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised Phase III trial of glufosfamide compared with best supportive care in metastatic pancreatic adenocarcinoma previously treated with gemcitabine.

A. V. Pavlovsky, T. Ciuleanu, G. Bodoky, 2009, European journal of cancer.

Phase II study of the safety and antitumor activity of the hypoxia-activated prodrug TH-302 in combination with doxorubicin in patients with advanced soft tissue sarcoma.

K. Ganjoo, B. V. Van Tine, S. Kroll, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase I study of TH-302, an investigational hypoxia-targeted drug, and dexamethasone in patients with relapsed/refractory multiple myeloma.

J. Laubach, P. Richardson, P. Armand, 2013 .

Phase 1 Study of the Safety, Tolerability, and Pharmacokinetics of TH-302, a Hypoxia-Activated Prodrug, in Patients with Advanced Solid Malignancies

Suzanne F. Jones, M. Lacouture, M. Borad, 2011, Clinical Cancer Research.

A practical methodology for patient release after tositumomab and (131)I-tositumomab therapy.

M. Kaminski, R. Wahl, D. Regan, 2002, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Mcclain Kl, Zipf Te: Measurement of Residual Leukemia during Remission in Childhood Acute Lymphoblastic Leukemia. N Engl J Med

Akashi, M. Caligiuri, T. Miyamoto, 2022 .

High intensity 125-iodine (125I) plaque treatment of uveal melanoma.

J. Quivey, T. Phillips, D. Char, 1993, International journal of radiation oncology, biology, physics.

A comparison of cause-specific melanoma mortality and all-cause mortality in survival analyses after radiation treatment for uveal melanoma.

J. Quivey, D. Char, S. Kroll, 1998, Ophthalmology.

Cytomorphometry of uveal melanoma. Comparison of fine needle aspiration biopsy samples with histologic sections.

B. Ljung, D. Char, S. Kroll, 1991, Analytical and quantitative cytology and histology.

Durable remissions from fludarabine followed by the iodine I-131 tositumomab Bexxar therapeutic regimen for patients with previously untreated follicular non-Hodgkin's lymphoma (NHL).

J. Leonard, S. Kroll, L. Kostakoglu, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Retinal detachment in AIDS: long term results after repair with silicone oil

S. Kroll, D. Schwartz, M. Zarbin, 1997, The British journal of ophthalmology.

A dose-escalation study of tositumomab and iodine I 131 tositumomab (Bexxar) in pts with previously treated non-Hodgkin's lymphoma (NHL) with > 25% bone marrow involvement.

J. Leonard, S. Kroll, L. Kostakoglu, 2004, Journal of Clinical Oncology.

Coincident systemic malignant disease in uveal melanoma patients.

D. Char, S. Kroll, N. Kindy-Degnan, 1989, Canadian journal of ophthalmology. Journal canadien d'ophtalmologie.

Long term visual outcome of radiated uveal melanomas in eyes eligible for randomisation to enucleation versus brachytherapy.

J. Quivey, D. Char, S. Kroll, 1996, The British journal of ophthalmology.

Phase 2 study of tarloxotinib bromide (TRLX) in patients (pts) with EGFR-Mutant, T790M-Negative NSCLC progressing on an EGFR TKI.

R. Doebele, B. Solomon, D. Gerber, 2016 .

Robin L. Jones, W. Read, H. Tawbi, 2017, The Lancet. Oncology.

Das Deutsche Pilz-Keratitis-Register

A. Viestenz, S. Kroll, V. Kakkassery, 2019, Der Ophthalmologe.

Abstract B185: Bench to bedside experience with TH‐302: A tumor‐selective hypoxia‐activated prodrug as a promising treatment for prostate cancer

A. Armstrong, S. Kroll, E. Chiorean, 2009 .